Harnessing molecular signatures to deliver personalised B-cell targeted therapies in Sjogren's syndrome

点击翻译按钮获取中文摘要

Sjogren Syndrome (SS) is a persistent/long-lasting disease characterised by inflammation of the glands that produce moisture in the body. The signs and symptoms range from dryness, joint pain and fatigue affecting nearly all patients, to severe involvement of organs and systems, in a more limited group. The cause of SS remains unknown but is associated with defects in the immune system. Our preliminary research showed that specialised types of immune cells, called B and T cells behave more abnormally in adults with SS contributing to organ and tissue damage. We want to understand why immune cells and genes they transcribe are different in adults with SS and healthy controls (HC) of the same sex and age, and try to identify how we can influence the way these cells behave, which will hopefully lead to better treatments for patients with SS. To be able to look into this, we established a collaboration with a pharmaceutical company, GSK, who run a study in patients with SS and treated them with two different therapies which target B cells, called Rituximab and Belimumab. They used these treatments alone as well as in combination and compared how effective they are versus normal treatment (which we call standard of care). In addition to assessing patient response, they collected blood samples and also salivary gland biopsies (small pieces of tissue removed to view under the microscope to help diagnosing SS).What are our research aims?Objective-1: Define the fingerprints associated with the genes that are transcribed by patients blood cells to look for differences between :(i) SS disease vs. healthy controls; (ii) SS disease which is active versus well controlled (iii) SS patients who responded to Belimumab and Rituximab versus non-responders (by looking at samples collected at baseline vs 24 weeks post B-cell targeting therapies/placebo).Objective-2: Establish shared fingerprints between blood and salivary gland tissue that reflect disease activity (combining patients from the GSK trial and UCL cohorts) and potential response to B cell targeted therapies at the end of the the GSK trial